Diabetic foot ulcer outcomes depend as much on who the patient is as on what the clinician does, so a raw healing rate says little about quality of care. A clinic with a 40% closure rate may be treating sicker patients better than a clinic with 60%. Comparing the two means first agreeing on which outcome is being measured, then adjusting for the patients each clinic actually sees.
This matters because diabetic foot ulcer (DFU) data is used to judge clinicians, set coverage policy, and defend therapies. Most of that data was either collected under trial conditions that exclude complex patients or reported without adjustment for case mix. The sections below cover which outcomes count, what the landmark sources do and do not tell you, and how risk-adjusted registry data closes the gap.
Which Outcomes Define Success in Diabetic Foot Ulcer Care?
Six outcomes define success: complete closure, time to closure, recurrence, amputation (minor versus major), hospitalization, and mortality. Closure is the one most often reported because it is easy to count. It is also the least complete, since a wound that closes and reopens two months later is counted as a success in many datasets, and a wound that “closes” because the limb was amputated may not be counted as a failure at all.
Amputation level matters clinically. A minor amputation (at or below the ankle, such as a toe or ray resection) preserves a functional limb, while a major amputation (below or above the knee) changes mobility, caregiving needs, and survival. Reporting them as one “amputation” number hides that difference.
Definitions decide whether numbers can be compared
Two sources can report “healing rate” and mean different things. Common variations include:
- The time window: closure by 12 weeks, 20 weeks, or 12 months.
- The closure standard: full epithelialization with no drainage, confirmed at a second visit (often two weeks later), versus a single clinician observation.
- The denominator: all patients who started care, or only those who completed the protocol.
- The unit: per patient or per wound, which matters when one patient has several ulcers.
Until these are standardized, a figure from one paper cannot be set beside a figure from your clinic without caveats.
Patient-centered outcomes and process measures
Patients also care about ambulation, pain, function, and quality of life, none of which closure captures. Separately, process measures such as documented offloading, vascular assessment, and infection screening describe what the clinician did rather than what happened to the patient. Processes are useful because they are within the clinician’s control, but they are not outcomes, and a reporting program that relies only on them tells you little about results.
What Do Published Diabetic Foot Ulcer Outcomes Actually Report?
Several sources anchor the literature, and each answers a different question. The International Working Group on the Diabetic Foot (IWGDF) publishes evidence-based guidelines on prevention and management, updated every four years; the current 2023 edition is due for its next update in 2027. These guidelines grade interventions such as offloading, infection management, and revascularization, but they are not a source of clinic-level benchmarks.
The widely cited review by Armstrong, Boulton, and Bus in the New England Journal of Medicine (2017), “Diabetic Foot Ulcers and Their Recurrence,” summarizes lifetime ulcer risk among people with diabetes and the high rate of recurrence after healing. Its central message is that closure is not the end of the story: remission is fragile. The authors estimate that 19% to 34% of people with diabetes will develop a foot ulcer in their lifetime, and that roughly 40% of patients have a recurrence within one year of healing, almost 60% within three years, and 65% within five years.
The trial control-arm benchmark
For healing, a commonly used reference point comes from the control arms of randomized trials, where patients receiving standard care (debridement, offloading, moist dressings) reach closure at 12 weeks in roughly a quarter to a third of cases. A 1999 meta-analysis by Margolis and colleagues found weighted mean healing rates of 24% at 12 weeks and 31% at 20 weeks, and a 2020 update put 12-week closure near 33%. Treat these as approximate benchmarks, because they vary with wound size, duration, and how closure was defined, and because trial participants are healthier than the patients most wound centers treat.
Amputation and mortality
Reported amputation rates and five-year mortality after a DFU differ widely across studies. Populations differ in age, vascular disease, kidney function, and access to care, and settings range from specialized multidisciplinary clinics to community populations. Mortality after a DFU is high compared with people with diabetes but no ulcer: a 2023 JAMA review estimated five-year mortality at about 30%, rising above 70% after a major amputation. Still, no single number fits every population. When you cite one, name the study, the cohort, and the follow-up period, and avoid applying a figure from one setting to another.
Why Do Trial Results and Real-World Diabetic Foot Ulcer Outcomes Differ?
Randomized trials need a clean signal, so they exclude many of the patients wound centers treat daily. Typical exclusions include very chronic wounds, poorly controlled HbA1c, significant peripheral arterial disease (PAD), advanced renal disease, active or deep infection, and patients unlikely to adhere to follow-up or offloading. Each exclusion improves internal validity and narrows who the result applies to.
Consider an illustration. A trial-eligible patient is a 55-year-old with a four-week-old plantar ulcer, adequate perfusion, an HbA1c in a controllable range, no infection, and reliable transportation. A clinic patient might be a 60-year-old with a six-month-old wound, dense neuropathy, PAD with reduced toe pressures, stage 4 chronic kidney disease, a prior transmetatarsal amputation, and difficulty wearing an offloading device. The first patient resembles the people in the control arm. The second would likely never have been enrolled, and their expected healing trajectory is very different.
Applying trial benchmarks to the second patient produces a misleading conclusion: a clinic whose outcomes fall below the trial rate looks like it is underperforming, when it may be treating exactly the patients the trial left out.
Why the gap reaches coverage policy
The gap becomes consequential when payers and coverage contractors rely on trial evidence to define when a therapy is “reasonable and necessary.” If the trials excluded complex patients, the evidence base cannot show whether a therapy helps them, and policy can end up restricting treatment for the very population with the greatest need. The absence of trial evidence is then read as evidence of absence. Real-world data that includes these patients, collected consistently and adjusted for their risk, is the practical way to fill that void. Comparative effectiveness work in wound care depends on it.
What Patient and Wound Factors Drive Diabetic Foot Ulcer Outcomes?
Outcomes are shaped by factors that exist before the first visit. The major prognostic variables include:
- Wound size and duration: larger and older wounds heal more slowly and less often.
- Depth: Wagner grade or University of Texas classification captures depth, and the latter also incorporates infection and ischemia.
- Infection: including osteomyelitis, which changes both the treatment course and the odds of amputation.
- Ischemia: impaired perfusion limits healing regardless of local wound care.
- Glycemic control: HbA1c and its trend.
- Renal function: particularly end-stage kidney disease and dialysis.
- Smoking status and offloading adherence, the latter being among the strongest modifiable factors.
Early area reduction as a predictor
One of the best-known prognostic findings is that early response predicts eventual closure. Sheehan and colleagues (Diabetes Care, 2003) found that the percentage reduction in wound area after four weeks of standard care predicted healing at 12 weeks. Clinically, this gives a checkpoint: a wound that has not meaningfully shrunk by about a month is a candidate for reassessment of perfusion, infection, offloading, and the treatment plan. In that trial of 203 patients, the dividing line was a 53% area reduction: patients above the four-week median healed 58% of the time by week 12, versus 9% of those below it. Apply the threshold with attention to the population studied.
Care setting changes the case mix
Setting is not a quality signal on its own. A hospital outpatient wound center may receive referrals of complex, long-standing wounds. A podiatry practice may see earlier, less advanced ulcers. Skilled nursing facility and home health patients tend to be older, more frail, and less mobile, which complicates offloading. A difference in raw outcomes between these settings can reflect who walks in the door rather than how well they are treated, which is the problem risk adjustment is built to solve.
How Does Risk Adjustment Make Diabetic Foot Ulcer Outcomes Comparable?
Risk adjustment uses patient and wound characteristics to estimate how likely each patient is to reach a given outcome. Summed across a clinic’s patients, those probabilities give an expected result. The observed result is what actually happened. The observed-to-expected (O/E) ratio compares them: above 1 for a favorable outcome means the clinic did better than its case mix predicted, and below 1 means worse.
An illustrative example
Suppose two clinics each report that 45% of their DFU patients reached closure within 20 weeks. Clinic A treats mostly early-stage, adequately perfused wounds, and a risk model predicts that about 55% of its patients should have healed. Clinic B treats many chronic wounds with PAD and kidney disease, and the model predicts about 35%. Identical raw rates, very different performance: Clinic A is below expectation, and Clinic B is well above it. These numbers are hypothetical, but the pattern is the one unadjusted comparison hides. Dr. Caroline Fife has described scoring well under MIPS with a 33% DFU healing rate because the measure accounted for how difficult her patients’ wounds were to heal.
The incentive problem
Unadjusted scores penalize clinicians who accept difficult patients. If a score affects payment or reputation, the rational response is to avoid high-risk referrals, which harms the patients who most need specialized care. Adjustment removes that incentive by evaluating each clinician against a realistic expectation.
What makes adjusted outcomes credible
Adjusted numbers will only survive scrutiny from a payer or administrator if three conditions hold:
- Standardized definitions: closure, recurrence, and amputation level defined identically across every contributing site.
- Sufficient sample size: small denominators produce unstable ratios, so results for a single clinician need enough cases, or wider confidence intervals.
- Transparent methodology: published covariates, model approach, and data-quality checks so the result can be reproduced and challenged.
How Can a Registry Turn Diabetic Foot Ulcer Outcomes into MIPS Credit and Evidence?
A Qualified Clinical Data Registry (QCDR) is a CMS-approved entity that can submit quality measures to the Merit-based Incentive Payment System (MIPS) on behalf of clinicians, including measures it develops itself. For wound care, that means reporting measures designed around wound and limb outcomes instead of generic measures borrowed from primary care or surgery. US Wound & Podiatry Registries (USWR) operates as a QCDR for this purpose. For the 2026 performance year, USWR offers eight CMS-approved wound care measures, including diabetic foot ulcer healing or closure and adequate offloading, alongside measures for venous leg ulcers, pressure ulcers, nutrition, arterial assessment, and AI-based wound measurement. Measure names, scoring, and requirements change from year to year, so review how wound care practitioners report MIPS before planning your submission.
Workflow without double entry
The practical barrier for most clinics is duplicate documentation. A registry that connects to the EHR can pull structured data, such as wound measurements, classification, and vascular status, from what clinicians already chart, rather than asking staff to rekey it. Dashboards then show performance at the clinic and clinician level, so a medical director or quality lead can see roster-wide results, identify outliers, and act on the four-week checkpoint described earlier rather than finding problems at year end.
From reporting to evidence and advocacy
Aggregated across many sites, registry data becomes real-world evidence on the complex patients trials omit. That evidence can be used by researchers, manufacturers, and policymakers. For example, data from the USWR’s Hyperbaric Oxygen Therapy Registry were used in the AMA RUC’s revaluation of physician payment for hyperbaric chamber supervision, documenting the comorbidity burden of patients undergoing hyperbaric oxygen therapy. The broader point holds regardless: when a specialty faces payment or coverage threats, credible, risk-adjusted outcomes are among the few tools that can answer them with data.
How Can You Make Diabetic Foot Ulcer Outcomes Meaningful for Your Practice?
Diabetic foot ulcer outcomes carry weight only when they are defined consistently and adjusted for the patients behind them. A closure rate without a time window, a closure standard, and a case-mix adjustment is a number, not evidence.
Start by asking whether your current reporting reflects your actual patient mix. Check whether it separates minor from major amputation, tracks recurrence after closure, and compares you with an expectation built from patients like yours rather than a trial population. If it does not, a specialty registry is worth evaluating. Learn more about our services.
Recent Comments